Seeking Alpha

Nektar Therapeutics (NKTR +15% premarket) will receive up to $1.12B from AstraZeneca (AZN) for...

Nektar Therapeutics (NKTR +15% premarket) will receive up to $1.12B from AstraZeneca (AZN) for its NKTR-118 and NKTR-119 constipation drugs, including $125M upfront to license NKTR-118, another $235M if it achieves certain milestones, and $375M more if it hits commercial success milestones.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector